BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy BioDlink proudly announces Junshi Biosciences' IND approval for JS212, a bispecific ADC aimed at treating various cancers. This milestone showcases advanced therapeutic advancements.

BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy #China #Suzhou #BioDlink #Junshi_Biosciences #JS212